https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/protein-responsible-rare-childhood-disorder-gives-clues-common-neurodegenerative-conditions/
Protein responsible for rare childhood disorder gives clues to common neurodegenerative conditions
9 Sep 2015, 4:10 p.m.
A new mutation in the protein STAT2 has been identified in patients with mitochondrial disease. These findings could also be beneficial for more common neurodegenerative diseases, including Alzheimer’s, Huntington’s and Parkinson’s diseases.Mitochondria are dynamic organelles that constantly go through elongation (fission), and shortening (fusion) in order to share their genetic material and contents. There is a delicate balance between these fission and fusion events, which are very important for normal cell function. Modulation of this dynamic can lead to mitochondrial disorders.
The team identified a novel mutation in a gene called STAT2, which codes for a protein involved in the innate immune system, in two children presenting with severe neurological deterioration following viral infection. The researchers also observed that the mitochondria of these two patients and a third unrelated STAT2-deficient patient, appeared abnormally elongated in shape. Through studying the function of these organelles in the lab, the researchers were able to show that one of the proteins involved in mitochondrial fission is inactive in cells that lack the STAT2 protein.
These findings imply that STAT2 is a novel regulator of mitochondrial fission. It is also the first study to link the innate immune system to mitochondrial function. It is hoped that new therapeutic targets for mitochondrial diseases can be developed from these findings, for which currently there are no effective cure.
This study was led by BRC-supported Professor Shamima Rahman and is published in Brain.
Celebrating 25 years of saving children’s lives with gene therapy
Marking 25 years since delivering the first ground-breaking gene therapy here at GOSH, having now treated more than 135 children with rare and life-threatening conditions across the world.
A catalyst to unlock the next generation of research leaders
The NIHR GOSH Biomedical Research Centre (BRC) Fellowships are transforming early-career researchers into independent leaders - driving innovation, attracting millions in funding and shaping the future of paediatric science.
Landmark decision to screen for spinal muscular atrophy at birth
Great Ormond Street Hospital (GOSH) is delighted at the announcement that newborn babies in England will be offered screening for spinal muscular atrophy (SMA) through the newborn blood spot, or "heel prick", test programme.
Building the next generation of paediatric research leaders
From early career clinicians to emerging scientists, the NIHR GOSH Biomedical Research Centre (BRC)’s Academic Training Weekend is shaping the future of paediatric research - bringing together talent, expertise and ambition from across the UK.